Usage of the wearable cardioverter-defibrillator during pregnancy

Olic, J.-Jacqueline; Stöllberger, Claudia; Schukro, Christoph; Odening, Katja E.; Reuschel, E; Fischer, Marcus; Veltmann, Christian; Duncker, David; Baessler, Andrea

doi:10.1016/j.ijcha.2022.101066

Cited by 3 publications

(2 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Olic et al also reports patients with inherited and congenital heart disease stopping WCD use due to incompliance and discomfort, but that may be influenced by the fact that their patients were pregnant at the time and consequently of younger age ( 32 ). In our previous study regarding age differences in WCD use, the wear hours in younger patients (age < years) tended to be lower (20.11 ± .88 h) and predictors for worse compliance were younger age and non-ischemic cardiomyopathy ( 33 ).…”

Section: Discussionmentioning

confidence: 99%

No beneficial use of the wearable cardioverter defibrillator among patients suffering from inherited and congenital heart disease: data from a European multicenter registry

Koepsel,

Dreher,

Blockhaus

et al. 2024

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundData on the use of the wearable cardioverter defibrillator in patients suffering from inherited and congenital heart disease are limited. Consequently, evidence for guideline recommendations in this patient population is lacking.MethodsIn total 1,675 patients were included in a multicenter registry of eight European centers. In the present cohort, we included 18 patients suffering from congenital and inherited heart disease.ResultsNine patients (50%) were male with a mean age of 41.3 ± 16.4 years. Four patients suffered from hypertrophic cardiomyopathy (HCM), four patients suffered from non-compaction cardiomyopathy (NCCM), two patients were diagnosed with arrhythmogenic right ventricular cardiomyopathy (ARVC) and one patient suffered from muscular dystrophy of the limb-girdle type with cardiac involvement, secondary cardiomyopathy. Three patients presented with Brugada syndrome (BrS). One patient suffered from long-QT syndrome type 1 (LQTS1). Furthermore, two patients had congenital heart defects and one patient suffered from cardiac sarcoidosis (CS). There were no appropriate/inappropriate shocks with the WCD in this cohort. One patient had recurrent self-limiting sustained ventricular tachycardia during the wear time, but actively inhibited a shock and was hospitalized. The compliance rate in this cohort was 77.8% with a mean wear time of 45.3 ± 26.9 days with a mean follow-up time of 570 ± 734 days. 55.6% (10/18) of the patients received an ICD after WCD wear time.ConclusionsThis retrospective study of patients with inherited and congenital heart disease shows that WCD use is not beneficial in the majority of patients with inherited and congenital heart disease.

show abstract

Section: Discussionmentioning

confidence: 99%

No beneficial use of the wearable cardioverter defibrillator among patients suffering from inherited and congenital heart disease: data from a European multicenter registry

Koepsel,

Dreher,

Blockhaus

et al. 2024

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“… 53 , 55 , 60 , 80 A recent study examining the use of WCDs in pregnancy found that arrhythmia detection remained excellent despite the altered anatomy and physiology, but since no shocks were delivered in these patients, the efficacy of these devices remains unclear. 81 …”

Section: Managementmentioning

confidence: 99%

Peripartum Cardiomyopathy: Risks Diagnosis and Management

Carlson¹,

Schultz²,

Ramu³

et al. 2023

JMDH

View full text Add to dashboard Cite

Peripartum cardiomyopathy is a rare cause of heart failure that occurs during late pregnancy or in the early postpartum period. Delays in diagnosis may occur as symptoms of heart failure mimic those of normal pregnancy. The diagnosis should be considered in any pregnant or postpartum woman with symptoms concerning for heart failure. If there are clinical concerns, labs including N-terminal pro-BNP should be checked, and an echocardiogram should be ordered to assess for systolic dysfunction. Prompt medical treatment tailored for pregnancy and lactation is essential to prevent adverse events. Outcomes are variable, including complete recovery, persistent myocardial dysfunction with heart failure symptoms, arrhythmias, thromboembolic events, and/or rapid deterioration requiring mechanical circulatory support and cardiac transplantation. It is essential that care is provided as part of a multidisciplinary cardio-obstetrics team including obstetrics, cardiology, maternal fetal medicine, anesthesiology, and nursing. All women with peripartum cardiomyopathy should have close follow-up with a cardiologist, although optimal duration of medical therapy following complete recovery is unknown. Women considering a subsequent pregnancy require preconception counseling and close collaboration between obstetrics and cardiology throughout pregnancy.

show abstract

Cardiac implantable electronic devices in pregnancy: A position statement

Castleman,

Curtis,

Fox

et al. 2024

BJOG

View full text Add to dashboard Cite

The aim of this document is to provide guidance for the management of women and birthing people with a permanent pacemaker (PPM) or implantable cardioverter defibrillator (ICD). Cardiac devices are becoming more common in obstetric practice and a reference document for contemporary evidence‐based practice is required. Where evidence is limited, expert consensus has established recommendations. The purpose is to improve safety and reduce the risk of adverse events relating to implanted cardiac devices during pregnancy, birth and the postnatal period.

show abstract

Usage of the wearable cardioverter-defibrillator during pregnancy

Cited by 3 publications

References 41 publications

No beneficial use of the wearable cardioverter defibrillator among patients suffering from inherited and congenital heart disease: data from a European multicenter registry

No beneficial use of the wearable cardioverter defibrillator among patients suffering from inherited and congenital heart disease: data from a European multicenter registry

Peripartum Cardiomyopathy: Risks Diagnosis and Management

Cardiac implantable electronic devices in pregnancy: A position statement

Contact Info

Product

Resources

About